<DOC>
	<DOCNO>NCT00180102</DOCNO>
	<brief_summary>AML2003 prospective randomize trial , investigate value early allogeneic stem cell transplantation aplasia induction therapy high risk patient acute myeloid leukemia .</brief_summary>
	<brief_title>AML2003 - Standard-Therapy v Intensified Therapy Adult Acute Myeloid Leukemia Patients &lt; = 60 Years</brief_title>
	<detailed_description>AML2003 prospective randomize trial , investigate value early allogeneic stem cell transplantation aplasia induction therapy high risk patient acute myeloid leukemia . A rapid analysis risk-factors ( cytogenetics , FLT3 status , clearance blast first induction ) donor situation utmost importance . For `` fast search '' diagnostic , accomplish enclosed patient , significant resource provide , take load participate center . Furthermore , relevance autologous transplantation benefit additional substance within postremission therapy m-AMSA mitoxantrone investigate . There up-front randomisation four therapy arm two cross-classifying factor two stage ( intensify vs. standard therapy Ara C vs. Ara C+ mitoxantrone + m-AMSA ) . Thus , intergroup treatment schedule German Competence Network integrate AML2003 study central element 25 % patient treat accordingly . In intensified therapy arm risk-adapted priority-based therapy implement , include early allogeneic consolidate autologous stem cell transplantation , respectively . In addition clinical question , detailed concomitant research program initiate AML2003 study , get good view heterogeneity AML open new way `` custom-made '' therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Amsacrine</mesh_term>
	<criteria>de novo secondary acute myeloid leukemia FABsubtypes M0M2 M4M7 de novo secondary myelodysplastic syndrome WHOtype RAEB2 age 16 60 year write informed consent severe comorbidities severe , uncontrolled complication leukemia prior therapy AML/MDS simultaneous hematological malignancy HIVInfection know allergy study medication pregnancy miss write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>risk adapt treatment</keyword>
	<keyword>early allogeneic stem cell transplantation</keyword>
	<keyword>autologous stem cell transplantation</keyword>
</DOC>